Aims/Introduction: Vaspin is linked to obesity and its metabolic abnormalities. However, the role of vaspin serum levels in diabetic retinopathy (DR) is unknown. In the present study, we investigated the association between serum levels of vaspin and both DR and vision-threatening DR. Materials and Methods: This was a cross-sectional single-center observational study from December 2018 to September 2019. We evaluated circulating serum levels of vaspin in 372 participants with type 2 diabetes. DR was screened through detailed ocular examination. DR patients were also divided two groups: vision-threatening DR and non-visionthreatening DR. The relationship between vaspin and DR was investigated by univariate and multivariate logistic regression analyses, and the results are shown as odds ratios with 95% confidence intervals. Results: The vaspin serum levels of 372 patients were obtained, with a median value of 1.50 ng/mL (interquartile range 0.94-2.18 ng/mL). The median age of those patients was 53 years (interquartile range 44-62 years), and 44.4% were women. Patients with DR and VDTR had significantly increased vaspin serum levels (P < 0.001 and P < 0.001). A multivariable regression model found that patients with high levels of vaspin were approximately 1.85-fold (odds ratio for per unit increase 1.85, 95% confidence interval 1.43-2.55; P < 0.001) more likely to experience DR, and 3.76-fold (odds ratio for per unit increase 3.76, 95% confidence interval 2.05-6.55; P < 0.001) more likely to experience VTDR. The predictive value of vaspin was stronger in women than in men. Conclusion: Higher vaspin serum levels were associated with an increased risk of DR and VDTR in patients with type 2 diabetes, which showed that vaspin is an important indicator factor for DR.
AIM: To identify risk factors of recurrence of this disorder after intravitreal ranibizumab (IVR) monotherapy. METHODS: Totally 33 eyes of 19 patients who underwent initial IVR treatments for type 1 retinopathy of prematurity (ROP) at our center were retrospectively reviewed between April 1, 2016 and December 31, 2017. Patient demographics, the side of ROP, multiple gestations, Apgar scores, zone, stage, plus disease, postmenstrual age at injection, surfactant therapy, blood transfusion therapy, hemorrhage before IVR, hemorrhage after IVR, gestational diabetes mellitus, pregnancy-induced hypertension, anemia, intraventricular hemorrhage, sepsis, respiratory distress syndrome, carbohemia, and congenital heart defects were recorded. Adjusted hazard ratios (HRs) and 95% confidence intervals were determined after adjusting for potential confounders using multivariate proportional Cox regression. RESULTS: Of the 33 eyes, 12 (36.4%) had ROP recurrences 45.3 (5.1, 50.9)mo after initial IVR treatments. The independent risk factors for ROP recurrences were zone (¢ò vs ¢ñ, HR: 0.056, P=0.003) and gestational diabetes mellitus (no vs yes, HR: 0.095, P<0.001). The mean uncorrected visual acuity for four recurrence eyes was 0.46 logMAR (0.13, 0.70) at 55.0 (51.0, 58.9) mo after the initial IVR treatment. The mean uncorrected visual acuity for 10 eyes without recurrence was 0.46 logMAR (0.19, 0.63) at 48.0 (43.8, 58.4) mo after the initial IVR treatment. CONCLUSION: Two independent risk factors for type 1 ROP recurrence after IVR treatment involving zone¢ñand gestational diabetes mellitus are identified, and the mean uncorrected visual acuity is 0.46 logMAR at 51.0 (44.0, 58.9)mo. The findings of this study are important for follow-up management and for improving the visual function of ROP patients.
Purpose: The risk factors for retinopathy of prematurity (ROP) recurrence in patients with intravitreal ranibizumab (IVR) treatments after long-term follow-up are unclear, so we aimed to identify risk factors of recurrence of this disorder after IVR monotherapy.Methods: We retrospectively reviewed 33 eyes of 19 patients who underwent initial IVR treatments for type 1 ROP at our center between April 1, 2016 and December 31, 2017. Patient demographics, the side of ROP, multiple gestations, Apgar scores, zone, stage, plus disease, postmenstrual age at injection, surfactant therapy, blood transfusion therapy, hemorrhage before IVR, hemorrhage after IVR, gestational diabetes mellitus, pregnancy-induced hypertension, anemia, intraventricular hemorrhage, sepsis, respiratory distress syndrome, carbohemia, and congenital heart defects were recorded. Adjusted hazard ratios (HRs) and 95% confidence intervals were determined after adjusting for potential confounders using multivariate proportional Cox regression. Results: Of the 33 eyes, 12 (36.4%) had ROP recurrences 45.3 (5.1, 50.9) months after initial IVR treatments. The independent risk factors for ROP recurrences were zone [Ⅱ vs. Ⅰ, hazard ratio (HR): 0.056, P = 0.003] and gestational diabetes mellitus (no vs. yes, HR: 0.095, P < 0.001). The mean uncorrected visual acuity for four recurrence eyes was 0.46 logMAR (0.13, 0.70) at 55.0 (51.0, 58.9) months after the initial IVR treatment. The mean uncorrected visual acuity for 10 eyes without recurrence was 0.46 logMAR (0.19, 0.63) at 48.0 (43.8, 58.4) months after the initial IVR treatment.Conclusions: We identified two independent risk factors for type 1 ROP recurrence after IVR treatment involving zone Ⅰ and gestational diabetes mellitus, and the mean uncorrected visual acuity was 0.46 logMAR at 51.0 (44.0, 58.9) months. The findings of this study are important for follow-up management and for improving the visual function of ROP patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.